These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Citrome L. Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264 [Abstract] [Full Text] [Related]
45. Tetrabenazine treatment for Huntington's disease-associated chorea. Ondo WG, Tintner R, Thomas M, Jankovic J. Clin Neuropharmacol; 2002 Nov; 25(6):300-2. PubMed ID: 12469001 [Abstract] [Full Text] [Related]
48. Valbenazine for Tardive Dyskinesia. Freudenreich O, Remington G. Clin Schizophr Relat Psychoses; 2017 Nov; 11(2):113-119. PubMed ID: 28742396 [Abstract] [Full Text] [Related]
49. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. Toglia JU, McGlamery M, Sambandham RR. J Clin Psychiatry; 1978 Jan; 39(1):81-7. PubMed ID: 147268 [Abstract] [Full Text] [Related]
56. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. J Clin Psychopharmacol; 2017 Apr; 37(2):231-238. PubMed ID: 28141621 [Abstract] [Full Text] [Related]